Introduction {#sec1-1}
============

Neurofibromatosis type 1 (NF1) is a common, progressive, autosomal dominant neurocutaneous disorder characterized by variable expressivity and a predisposition to the development of tumors. It is sporadic in about 50% of cases and affects 1 in 4000 individuals. Clinical features include café-au-lait macules, skin-fold freckles, Lisch nodules, and dermal neurofibromas.\[[@ref1]\]

Chronic myeloid leukemia (CML) is a clonal stem cell disorder characterized by increased proliferation of myeloid cells and the presence of Philadelphia chromosome. It is a common hematological malignancy. The natural history of CML is one of progression from a chronic phase via an accelerated phase to blast crisis, the blast crises is often refractory to treatment. Demonstration of the presence of Philadelphia chromosome is diagnostic. This chromosome leads to reciprocal translocation between chromosomes 9 and 22, juxtaposing the *BCR* and *ABL* genes onto chromosome 22, producing a fusion protein with abnormal tyrosine kinase activity;\[[@ref2]\] leading to a proliferative advantage in the affected cells.\[[@ref3]\]

Children with NFI have about 500 times greater risk of developing a malignant myeloid disorder than the normal children.\[[@ref4]\] NF-1 has been associated with nonlymphocytic leukemia such as juvenile myelomonocytic leukemia, myelodysplastic syndrome, and acute myeloid leukemia (AML) in children.\[[@ref4][@ref5]\] Childhood acute lymphoblastic leukemia (ALL) has been reported rarely in association with familial NF-1, with sporadic NF-1 showing a higher incidence of ALL than nonlymphocytic leukemia.\[[@ref6]\] The ratio of ALL to nonlymphocytic leukemia patients was 5:3 among sporadic NF-1 and 4:15 among patients with familial NF-1.\[[@ref5]\] However, this association between NF1 and malignant blood disorders has rarely been demonstrated in adults.\[[@ref4]\] A study by Julia *et al*. reported two adults who developed AML over a 10-year period, none developed CML, ALL, or chronic lymphocytic leukemia.\[[@ref4]\] Increased levels of Ras-GTP are found in the NF1-associated leukemias, these leukemic cells show hypersensitivity to GM-CSF and other cytokines.\[[@ref6]\] A literature search carried out in *PubMed* did not reveal any report of CML in adults with NF1. We present a patient with sporadic NF1 who subsequently developed CML.

Case Report {#sec1-2}
===========

Our patient was a 37-year old female teacher who was first seen in the hematology outpatient clinic following a referral from the dermatology clinic where she was being managed for type 1 neurofibromatosis (NF1). She presented with a 6-month history of easy fatigability and a left-sided abdominal mass. She had lost more than 10% of her weight in the past 6 months, and also complained of night sweats. Our patient was married with three children; there was no history of NF in either her nuclear or extended family.

On examination, she was chronically ill-looking and pale, afebrile to touch with Café-au lait spots over her trunk and lower limb, she also had neufibromas over her trunk \[[Figure 1](#F1){ref-type="fig"}\]. Her spleen was enlarged 16 cm below the left costal margin. There was no hepatomegaly.

![Presence of neurofibroma on the patient\'s back](IJD-56-423-g001){#F1}

The result of her full blood count is shown in [Figure 2](#F2){ref-type="fig"}, peripheral blood film and marrow aspirate were consistent with CML in chronic phase \[[Figure 3](#F3){ref-type="fig"}\]. A FISH analysis for *BCR/ABL* translocation showed that all 200 of her cells screened were positive for the *BCR/ABL* signal.
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![Bone marrow aspirate cytology showing spectrum of myeloid maturation](IJD-56-423-g003){#F3}

While awaiting her FISH analysis result, she was started on 2 g hydroxyurea (HU) daily, 300 mg allopurinol daily, and liberal oral fluids of at least 3L over 24 h. She was on hydroxyurea for about 6 months with fairly good results as shown in [Figure 2](#F2){ref-type="fig"}. When her FISH result was obtained, she was subsequently placed on 400 mg glivec daily. The patient did not tolerate glivec for very long, as she developed a pancytopenia, worst affected were the platelet count, she then started bleeding from the gums and developed menorrhagia, clotting profile done was normal apart from the presence of thrombocytopenia. Glivec was stopped and she was recommenced HU with poorer results this time, WBC did not respond and continued to rise.

Bone marrow aspirate confirmed that she had progressed into the blast state attempts at inducing remission with AML regimen failed.

Discussion {#sec1-3}
==========

The NF1 gene (a tumor suppressor gene) encodes neurofibromin which has a GTPase-activating protein (GAP) domain that regulates the action of Ras proteins.\[[@ref6]\] Ras proteins are signal switch molecules regulating cycling between an active guanosine triphosphate (GTP)-bound state (Ras-GTP) and an inactive guanosine diphosphate (GDP)-bound state (Ras-GDP).\[[@ref7]\] Ras activation is an essential component of proliferative responses of cells to extracellular stimuli.\[[@ref7]\] The absence of neurofibromin predisposes to tumor formation. As a result, people with NF1 are at increased risk for the development of malignancies such as leukemia, rhabdomyosarcoma, optic glioma, and brain tumors.\[[@ref8]\]

Given the relative common incidence of NF1 and the fact that patients with this disease have been shown by several authors to be predisposed to developing malignant diseases, it is difficult not to associate the CML which our patient developed with the underlying NF1 process; although to the best of our knowledge this association has not been previously made in an adult. It is possible that there was a synergistic action between the absence of neurofibromin and the presence of the tyrosine kinase activity of the *BCR/ABL* gene.

We are unable to explain why she ran a rather poor course, since other patients with CML and the Philadelphia chromosome have fared a lot better when placed on Glivec.

We conclude that dermatologist and other physicians that mange patients with NF1 should remain at alert about the possibility of their patients developing CML along with other malignancies.
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